DDInter1472 DDInter1435
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence. The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis. Thiazolidinediones, including pioglit
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Pioglitazone {u} (Compound) resembles {v} (Compound) Rosiglitazone
Pioglitazone {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Pioglitazone {u} (Compound) binds {v} (Gene) CYP2D6
Pioglitazone {u} (Compound) upregulates {v} (Gene) GPC1
Pioglitazone {u} (Compound) is included by {v} (Pharmacologic Class) Thiazolidinediones
Pioglitazone {u} (Compound) downregulates {v} (Gene) RGS2
Pioglitazone {u} (Compound) causes {v} (Side Effect) Acute coronary syndrome
Pioglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Pioglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norgestrel
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Pioglitazone (Compound) resembles Rosiglitazone (Compound)
Pioglitazone (Compound) treats type 2 diabetes mellitus (Disease)
Pioglitazone (Compound) binds CYP2D6 (Gene)
Pioglitazone (Compound) upregulates GPC1 (Gene)
Pioglitazone (Compound) is included by Thiazolidinediones (Pharmacologic Class)
Pioglitazone (Compound) downregulates RGS2 (Gene)
Pioglitazone (Compound) causes Acute coronary syndrome (Side Effect)
Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir